Raloxifene reduces the risk of local alveolar bone destruction in a mouse model of periodontitis combined with systemic postmenopausal osteoporosis

Ichimaru, Ryota; Tominari, Tsukasa; Yoshinouchi, Shosei; Matsumoto, Chiho; Watanabe, Kenta; Hirata, Michiko; Numabe, Yukihiro; Murphy, Gillian; Nagase, Hideaki; Miyaura, Chisato; Inada, Masaki

doi:10.1016/j.archoralbio.2017.09.017

Cited by 6 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a systematic review by Goyal et al revealed that women with severe periodontitis might have an increased risk of osteoporosis and should be examined for systemic bone health [9]. Ichimaru et al's findings also supported those of previous studies and revealed that the systemic treatment of an osteoporosisincreased BMD prevents alveolar bone loss caused by bacterial lipopolysaccharides [55]. Amedei et al [52] showed that the concurrent oestrogen deficiency and periodontitis led to increased alveolar bone damage in rats.…”

Section: Discussionmentioning

confidence: 83%

Melatonin Decreases Alveolar Bone Loss in Rats with Experimental Periodontitis and Osteoporosis: A Morphometric and Histopathologic Study

Altıntepe Doğan,

Toker,

Göze

2024

Biomedicines

View full text Add to dashboard Cite

Background: Periodontitis and post-menopausal osteoporosis include common chronic bone disorders worldwide, with similar etiopathogenetic events. This study evaluated the effect of systemic melatonin administration on the alveolar bone destruction of periodontitis progression in an experimental periodontitis model in osteoporotic rats. Methods: Forty-four Wistar rats were randomly divided into six experimental groups: control (C; n = 6); osteoporosis (O; n = 6); ligated periodontitis (LP; n = 8); osteoporosis- and periodontitis-induced (O+LP; n = 8); osteoporosis- and periodontitis-induced through 30 mg/kg/day melatonin administration (ML30; n = 8); and osteoporosis- and periodontitis-induced through 50 mg/kg/day melatonin administration (ML50; n = 8). The rats underwent bilateraloophorectomy and were maintained for 4 months to induce osteoporosis. After 4 months, 4-0 silk ligatures were placed submarginally around the mandibular first molar of each rat to induce experimental periodontitis, and melatonin was administered in the ML30 and ML50 groups for 30 days. Changes in alveolar bone levels were clinically measured, and tissues were histopathologically examined. Results: Osteoclastic activity in the LP and O+LP groups was significantly higher than in the other groups (p < 0.05), but was similar in the C, O, and ML30 groups (p > 0.05). RANKL activity was the highest in the O+LP group, while melatonin decreased RANKL activity in the melatonin-administered groups (p < 0.05). Systemically administered melatonin significantly decreased alveolar bone loss in the ML30 and ML50 groups compared with that in the periodontitis groups (p < 0.05). Conclusions: Melatonin inhibited alveolar bone destruction by decreasing the RANKL expression and inflammatory cell infiltration and increased osteoblastic activity in a rat model with osteoporosis and periodontitis.

show abstract

Section: Discussionmentioning

confidence: 83%

Melatonin Decreases Alveolar Bone Loss in Rats with Experimental Periodontitis and Osteoporosis: A Morphometric and Histopathologic Study

Altıntepe Doğan,

Toker,

Göze

2024

Biomedicines

View full text Add to dashboard Cite

show abstract

“…However, the effect of tamoxifen on periodontitis is unknown. A study by Ichimaru et al reported that raloxifene, one of the SERMs, increased the alveolar bone mass in patients with postmenopausal osteoporosis, and he concluded that this could be a useful approach in terms of preventing alveolar bone loss occurring due to periodontitis 35 . The fact that there was no difference between the control group and the tamoxifen users in terms of CAL and PD values and that better results were obtained from the AIs users support this information.…”

Section: Discussionmentioning

confidence: 94%

Evaluation of periodontal health in breast cancer patients undergoing tamoxifen or aromatase inhibitors drugs therapy: A cross‐sectional study

Ustaoğlu

Bulut

Üyetürk

et al. 2020

Special Care in Dentistry

View full text Add to dashboard Cite

AimTo study the dental and periodontal status of women with breast cancer (BCa) having tamoxifen or aromatase inhibitors (AIs) treatment in comparison with control healthy women.MethodsFifty‐one women on tamoxifen therapy, 52 women on AIs therapy and 52 systemically healthy controls were included in the study. The total number of teeth, the number of teeth indicated for extraction, the number of decayed teeth, and the duration of medication were recorded. Periodontal status was evaluated with gingival index (GI); plaque index (PI); bleeding on probing (BOP); probing depth (PD) and clinical attachment loss (CAL).ResultsThe lowest number of teeth and decayed teeth was found in AIs users (P < .001 and P = .003 respectively). The highest CAL value was seen in AIs users (P = .042) whereas no significant difference was found between the groups in terms of PI, GI, and PD (P = .102, P = .233, and P = .306, respectively). Lower PI was observed in patients using AIs for less than 2 years (P = .048).ConclusionsWhile tamoxifen did not affect the dental and periodontal condition, AIs medication adversely affected the dental and periodontal condition by more tooth loss and higher CAL.

show abstract

“…With an increasing incidence of osteoporosis [162,163], and metabolic disease-associated fractures, the socio-economic pressure will demand more and more answers to unsolved questions. Therefore, highly sophisticated bone cell co-cultures will evolve with the rapid development of biotechnology in the upcoming years.…”

Section: Recent Developments and Future Challengesmentioning

confidence: 99%

From the Clinical Problem to the Basic Research—Co-Culture Models of Osteoblasts and Osteoclasts

Zhu¹,

Ehnert²,

Rouß³

et al. 2018

IJMS

View full text Add to dashboard Cite

Bone tissue undergoes constant remodeling and healing when fracture happens, in order to ensure its structural integrity. In order to better understand open biological and clinical questions linked to various bone diseases, bone cell co-culture technology is believed to shed some light into the dark. Osteoblasts/osteocytes and osteoclasts dominate the metabolism of bone by a multitude of connections. Therefore, it is widely accepted that a constant improvement of co-culture models with both cell types cultured on a 3D scaffold, is aimed to mimic an in vivo environment as closely as possible. Although in recent years a considerable knowledge of bone co-culture models has been accumulated, there are still many open questions. We here try to summarize the actual knowledge and address open questions.

show abstract

Raloxifene reduces the risk of local alveolar bone destruction in a mouse model of periodontitis combined with systemic postmenopausal osteoporosis

Cited by 6 publications

References 27 publications

Melatonin Decreases Alveolar Bone Loss in Rats with Experimental Periodontitis and Osteoporosis: A Morphometric and Histopathologic Study

Melatonin Decreases Alveolar Bone Loss in Rats with Experimental Periodontitis and Osteoporosis: A Morphometric and Histopathologic Study

Evaluation of periodontal health in breast cancer patients undergoing tamoxifen or aromatase inhibitors drugs therapy: A cross‐sectional study

From the Clinical Problem to the Basic Research—Co-Culture Models of Osteoblasts and Osteoclasts

Contact Info

Product

Resources

About